Phase 1 Study of Single Agent ONX 0801

Currently enrolling

Study Design:  Non-randomized, open-label, dose finding trial
Patients:  Patients with solid tumors, including lymphomas, who have failed standard therapy or for which no standard curative therapy exists
Purpose:  To evaluate the safety and tolerability including dose limiting toxicity and maximum tolerated dose, as we as to determine the pharmacokinetics of ONX 0801
Location:  Select centers in the United Kingdom